Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.811
+0.061 (1.29%)
At close: Jun 5, 2025, 4:00 PM
4.650
-0.161 (-3.35%)
After-hours: Jun 5, 2025, 4:47 PM EDT
Alterity Therapeutics Employees
Alterity Therapeutics had 10 employees as of June 30, 2024. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$230,490
Profits / Employee
-$1,224,681
Market Cap
71.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ATHE News
- 24 days ago - Alterity Therapeutics Prominently Featured at the International MSA Congress - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - GlobeNewsWire
- 5 weeks ago - Appendix 4C – Q3 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 5 weeks ago - Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Raises A$40.0 million in Placement - GlobeNewsWire